Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026Business Wire · 5 days ago
Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual MeetingBusiness Wire · Oct 14, 2026
RxSight (NASDAQ:RXST) & Cerus (NASDAQ:CERS) Critical AnalysisDefense World · Sep 25, 2026
Cerus: This Blood-Safety Underdog Should Be Earning More RespectSeeking Alpha · Aug 18, 2026
Assenagon Asset Management S.A. Has $920,000 Stock Holdings in Cerus Corporation $CERSDefense World · Aug 16, 2026
Cerus Corporation (CERS) Q2 2026 Earnings Call TranscriptSeeking Alpha · Jul 30, 2026Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | -$0.01 | -$0.01 | Beat |
| Apr 30, 2026 | -$0.03 | -$0.01 | Beat |
| Mar 2, 2026 | -$0.01 | -$0.01 | Beat |
| Nov 6, 2025 | -$0.02 | -$0.00 | Beat |
| Aug 5, 2025 | -$0.02 | -$0.03 | Miss |
| May 1, 2025 | -$0.05 | -$0.04 | Beat |